TABLE 3.
Pathogen Identified at Baseline (MITT Population)*
| Pathogen category organism/group, n/N (%) | C/T + MTZ | MEM + placebo |
|---|---|---|
| Aerobic Gram-negative | 56/70 (80.0) | 18/21 (85.7) |
| Escherichia coli | 47/70 (67.1) | 13/21 (61.9) |
| ESBL producer† | 8/56 (14.3) | 3/18 (16.7) |
| Pseudomonas aeruginosa | 19/70 (27.1) | 6/21 (28.6) |
| Klebsiella pneumonia | 4/70 (5.7) | 0/21 (0.0) |
| ESBL producer† | 2/56 (3.6) | 0/18 (0.0) |
| Aerobic Gram-positive | 20/70 (28.6) | 10/21 (47.6) |
| Streptococcus anginosus | 9/70 (12.9) | 3/21 (14.3) |
| Streptococcus constellatus | 9/70 (12.9) | 3/21 (14.3) |
| Anerobic Gram-negative | 16/70 (22.9) | 5/21 (23.8) |
| Bacteroides fragilis | 13/70 (18.6) | 4/21 (19.0) |
| Bacteroides thetaiotaomicron | 4/70 (5.7) | 2/21 (9.5) |
| Anaerobic Gram-positive | 8/70 (11.4) | 2/21 (9.5) |
*Limited to pathogens with prevalence of ≥5% in ≥1 treatment arm.
†ESBL-producer status was determined for pathogens isolated from participants in the mMITT population with baseline aerobic Gram-negative pathogens.
C/T indicates ceftolozane/tazobactam; ESBL, extended-spectrum β-lactamase; MEM, meropenem; MITT, modified intent-to-treat; MTZ, metronidazole.